The promotional activities of pharmaceutical companies are regularly the target of criticism. Certain commentators imply that these businesses as a group devote too many resources to the promotion of their products, at the expense of their investments in research and development (R&D). Others maintain that these promotional activities alter the prescribing habits of doctors, which leads to a needless or even harmful rise in the consumption of drugs. Do these criticisms stand up to scrutiny?
Media Release, September 28, 2011 :: Pharmaceutical promotion, an essential expense
|Interview (in French) with Yanick Labrie (Argent, September 26, 2011)|